What is BLENREP?

BLENREP is a prescription medicine used to treat adults with multiple myeloma who have received at least 4 prior medicines to treat multiple myeloma, and their cancer has come back or did not respond to prior treatment. It is not known if BLENREP is safe and effective in children.

BLENREP is approved based on patient response rate. Studies are ongoing to confirm the clinical benefit of BLENREP for this use.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about BLENREP?

Before you receive BLENREP, you must read and agree to all of the instructions in the BLENREP REMS. Before prescribing BLENREP, your healthcare provider will explain the BLENREP REMS to you and have you sign the Patient Enrollment Form.

BLENREP can cause serious side effects, including:

Eye problems. Eye problems are common with BLENREP. BLENREP can cause changes to the surface of your eye that can lead to dry eyes, blurred vision, worsening vision, severe vision loss, and corneal ulcer. Tell your healthcare provider if you have any vision changes or eye problems during treatment with BLENREP.

REMS = Risk Evaluation and Mitigation Strategy.

Please see IMPORTANT SAFETY INFORMATION continued throughout and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.
Get to know BLENREP

When multiple myeloma comes back, you may have a lot of questions about how you will move forward. **There are ways to prepare for the future.**

**BLENREP is an IV infusion treatment for appropriate patients with relapsed or refractory multiple myeloma** that your healthcare provider may prescribe for you. It can be given in your healthcare provider’s office or an outpatient clinic over 30 minutes once every 3 weeks, and **does not require hospitalization.** Patients have had positive results with BLENREP treatment in clinical trials and it may be a good option for you.

Your healthcare provider and care team will be there for you throughout your treatment experience. We hope this guide will be a helpful and valuable resource.

**Remember, you are not alone in your multiple myeloma journey. There are treatment options available.**

---

**IMPORTANT SAFETY INFORMATION (CONT’D)***

- Your healthcare provider will send you to an eye specialist to check your eyes before you start treatment with BLENREP, prior to each dose of BLENREP, and for worsening symptoms of eye problems.
- Even if your vision seems fine, it is important that you get your eyes checked during treatment with BLENREP because some changes can happen without symptoms and may only be seen on an eye exam.
- You should use preservative-free lubricant eye drops at least 4 times per day during treatment with BLENREP as instructed by your healthcare provider.
- You should use caution when driving or operating machinery as BLENREP may affect your vision.
- Avoid wearing contact lenses during treatment with BLENREP unless directed by your eye specialist.

**BLENREP is the first antibody-drug conjugate (ADC) that targets B-cell maturation antigen (BCMA). It works in unique ways to help fight multiple myeloma.**

**BLENREP is appropriate for adult patients with relapsed or refractory multiple myeloma who have already received at least 4 prior therapies and whose cancer has come back or did not respond to prior treatment, including at least 1 from each of these classes of drugs:**

- An immunomodulatory agent like Revlimid (lenalidomide), Pomalyst (pomalidomide), or Thalomid (thalidomide)
- A proteasome inhibitor like Velcade (bortezomib), Kyprolis (carfilzomib), or Ninlaro (ixazomib)
- An anti-CD38 monoclonal antibody like Darzalex (daratumumab)

**BLENREP is approved based on patient response rate. Studies are ongoing to confirm the clinical benefit of BLENREP for this use.**

**The most common side effects of BLENREP include vision or eye changes such as findings on eye exam (keratopathy), decreased vision or blurred vision, nausea, low blood cell counts, fever, infusion-related reactions, tiredness, and changes in kidney or liver function blood tests. These are not all the possible side effects of BLENREP.**

**A Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program that the US Food and Drug Administration (FDA) can require for certain medicines with serious safety concerns. Because of the risk of eye problems, BLENREP is only available through a restricted program called the BLENREP REMS.**

Please see IMPORTANT SAFETY INFORMATION continued throughout and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.
BLENREP is an antibody-drug conjugate (ADC) that targets B-cell maturation antigen (BCMA)

An ADC is made of a cell-killing medication attached to an antibody, which is a type of protein produced by the immune system in response to a foreign substance.

The antibody of BLENREP seeks out and targets BCMA, a protein found on the surface of multiple myeloma cells in all patients.

The linked drug can then enter and kill multiple myeloma cells from the inside or activate your immune system to fight your cancer.

What is BCMA?

BCMA is a protein found on the surface of healthy plasma cells and cancerous myeloma cells alike. BCMA helps fuel cell growth and protects cells from dying.

BCMA is found at higher levels on myeloma cells.

IMPORTANT SAFETY INFORMATION (CONT’D)
Decrease in platelets (thrombocytopenia) is common with BLENREP, and can also be serious. Platelets are a type of blood cell that help your blood to clot. Your healthcare provider will check your blood cell counts before you start treatment with BLENREP and during treatment. Tell your healthcare provider if you have bleeding or bruising during treatment with BLENREP.

BLENREP works in different ways to fight multiple myeloma

BLENREP identifies cells that express BCMA and attaches directly to the BCMA protein.

BLENREP is then brought into the myeloma cells and releases medication that results in cell death. It is possible that healthy cells will be affected.

Once BLENREP attaches, the antibody part of the ADC attracts your body’s own immune system to recognize the cancerous myeloma cells and attack them.

BLENREP works differently from other multiple myeloma medications. It is the first and only ADC that targets BCMA, and also uses your body’s own immune system to recognize and attack the cancerous myeloma cells.

Please see IMPORTANT SAFETY INFORMATION continued throughout and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.
BLENREP was studied in patients with a broad range of characteristics

The results include the 97 patients who received the recommended dose of BLENREP. Patients received BLENREP as an intravenous infusion once every 3 weeks.

A broad range of patients with RRMM were included in the study:

- 53% were male with an average age of 65 years.
- patients had a median of 7 prior treatments across the population.
- patients who had received at least 3 prior treatments, including at least 1 from each of these classes of drugs:
  - an immunomodulatory agent, like Revlimid (lenalidomide), Pomalyst (pomalidomide), or Thalomid (thalidomide)
  - a proteasome inhibitor, like Velcade (bortezomib), Kyprolis (carfilzomib), or Ninlaro (ixazomib)
  - an anti-CD38 monoclonal antibody, like Darzalex (daratumumab)
- patients with high-risk cytogenetics,* which are abnormalities in your genes that may impact the course of your disease and treatment outcomes.
- patients who had impaired kidney function, which is a common complication in patients with RRMM.

*Presence of t(4;14), t(14;16), or 17p13del mutations. RRMM=relapsed or refractory multiple myeloma.

IMPORTANT SAFETY INFORMATION (CONT’D)

Infusion reactions are common with BLENREP, and can also be serious. Tell your healthcare provider or nurse right away if you get any of the following signs or symptoms of an infusion reaction while receiving BLENREP:

- chills or shaking
- dizziness
- redness of your face (flushing)
- feel like passing out
- itching or rash
- tiredness
- shortness of breath, cough, or wheezing
- fever
- swelling of your lips, tongue, throat, or face
- feel like your heart is racing (palpitations)

The most common side effects of BLENREP include vision or eye changes such as findings on eye exam (keratopathy), decreased vision or blurred vision, nausea, low blood cell counts, fever, infusion-related reactions, tiredness, and changes in kidney or liver function blood tests.

Response with BLENREP was seen in patients whose cancer had returned or progressed multiple times

The results below reflect the 97 patients who received the recommended single-agent dose of BLENREP. About a quarter of these patients had high-risk cytogenetics. Patients in the trial had received at least 3 and up to 21 prior treatment regimens. Patients’ responses were observed at 6 months and again at 13 months, to provide information on the longer-term benefits and risks of BLENREP.

At 6 months

Response to treatment

in approximately
31% of patients

Time to response

was about
6 weeks

Response lasted

at least
6 months

BLENREP showed a very good partial response or better

in 60% of patients
(18 out of 30 patients)

In the 97 patients evaluated at 6 months, 2 patients (2%) had a stringent complete response, 1 (1%) had a complete response, 15 (15%) had a very good partial response, and 12 (12%) had a partial response.

At 13 months

At the 13-month follow-up, approximately 32% of patients had a response to treatment. The response lasted approximately 11 months.

Please see IMPORTANT SAFETY INFORMATION continued throughout and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.
The most common side effects with BLENREP

The most common side effects (≥20%) seen in patients who received the recommended dose of BLENREP were:

- Vision or eye changes such as findings on an eye exam (keratopathy)
- Decreased vision or blurred vision
- Nausea
- Low blood cell counts
- Fever
- Infusion-related reactions
- Tiredness
- Changes in kidney or liver function blood tests

Eye problems reported in patients who received the recommended dose of BLENREP included:

- Keratopathy (71%)
- Decreased vision (53%)
- Blurred vision (22%)
- Dry eye (14%)

Of all the side effects, some led to treatment interruption, dose reduction, and treatment discontinuation.

- **8% of patients discontinued treatment permanently.** This was most commonly due to keratopathy (2.1%).

Because of the risk of eye problems, BLENREP is only available through a restricted program called the BLENREP REMS

**A Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program that the FDA can require for certain medicines to manage known or potential serious safety concerns associated with a medicine.**

- Before you receive BLENREP, you must read and agree to all of the instructions in the BLENREP REMS.
- Before prescribing BLENREP, your healthcare provider will explain the BLENREP REMS to you and have you sign the Patient Enrollment Form.
- You must be enrolled in the BLENREP REMS* and follow the REMS requirements for eye exams in order to receive BLENREP.

*Prescribers and healthcare settings must be certified in the BLENREP REMS prior to infusion.

To help monitor your eye health while receiving BLENREP, your oncologist will coordinate care with an eye care professional before each infusion.

If you already have an eye care professional, they can join your care team. The results of your eye exams will be shared with your oncologist to determine if you may need a dose reduction or dose hold with BLENREP.

Please see IMPORTANT SAFETY INFORMATION continued throughout and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.
With BLENREP, it is important that you get your eyes checked

Eye problems occurred in 77% of all 218 patients who received 2 different doses in the clinical trial. The most common side effect seen with BLENREP was keratopathy (76%).

Keratopathy is any change to the cornea, the outer surface of the eye. These changes that may occur to the cornea can also affect your vision. Over time, the cornea produces new cells to replace the affected ones.

**Symptomatic keratopathy occurs** when corneal changes affect a patient’s vision or cause dry eye.

**Asymptomatic keratopathy includes** changes that are seen on the eye exam, but the patient does not report any symptoms.

**Other eye problems included:**
- Decreased vision (55%)
- Blurred vision (27%)
- Dry eye (19%)

**Observations in the 218 patients who received 2 different doses of BLENREP**
- Among 165 patients who had keratopathy, 49% had eye symptoms, 65% had a clinically significant change in vision, and 34% had both eye symptoms and changes in vision.
- Of 149 patients with moderate to severe keratopathy, 39% recovered to mild findings or better after a follow-up of approximately 6 months, and the median time to resolution was 2 months (range: 11 days to 8.3 months).
- Of the 61% who had ongoing keratopathy, 28% were still on treatment, 9% were in follow-up, and in 24% the follow-up ended due to stopping participation, being lost to follow-up, or death.

**No permanent, complete vision loss was reported in the pivotal study**

**Signs of vision and eye changes**

Patients in the clinical trial experienced keratopathy and vision problems, which may have included the following symptoms:

- **Double vision**
- **Seeing halos around lights or photophobia (discomfort due to light)**
- **Blurred vision**
- **With normal vision, the image (or any external visual stimulus) will appear crisp without eye strain or irritation.**

- Of 41 patients who experienced decreased vision of worse than 20/40, **88% resolved and the median time to resolution was 22 days** (range: 7 days to 4.2 months).
- Of 3 patients who experienced decreased vision of 20/200 or worse, **all resolved and the median duration was 22 days** (range: 15 to 22 days).

![Snellen Visual Acuity chart](chart.png)

- **20/20 vision:** You can see clearly at 20 feet what should normally be seen at that distance.
- **20/50 vision:** You can see clearly at 20 feet what a person with normal vision can see at 50 feet.
- **20/200 vision:** You can see clearly at 20 feet what a person with normal vision can see at 200 feet.

In patients who recovered from moderate to severe keratopathy, the median time to resolution was 2 months (range: 11 days to 8.3 months)

Please see IMPORTANT SAFETY INFORMATION continued throughout and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.
Although eye problems with BLENREP can occur, they can be managed with supportive care and dosage modification.

Use preservative-free lubricant eye drops at least 4 times a day throughout treatment, as instructed by your healthcare provider.

For instructions on how to properly administer eye drops, visit eyedropinstructions.com

IMPORTANT SAFETY INFORMATION (CONT’D)

Before receiving BLENREP, tell your healthcare provider about all of your medical conditions, including if you:

• have a history of vision or eye problems.
• have bleeding problems or a history of bleeding problems.

Please see IMPORTANT SAFETY INFORMATION continued throughout and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.

BLENREP is a single agent that does not need to be combined with other multiple myeloma medications.

IV treatment infusion over at least 30 minutes

Available in your oncologist’s office or an outpatient clinic

Once every 3 weeks

Premedication with steroids is generally not required before your first infusion.

If you experience an infusion reaction, your healthcare provider may consider premedication, including a steroid, for any future infusions.

IV=intravenous.

Your healthcare provider will decide on the correct dose of BLENREP for you. The dose is calculated based on your body weight.

• If you experience an infusion reaction, your doctor will pause treatment and resume your dose at a slower rate (infused over a longer period of time) after symptoms resolve.
• If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

Dose modifications

• 54% of patients experienced a treatment interruption. Side effects that led to an interruption in more than 3% of patients included keratopathy (47%), blurred vision (5%), dry eye (3.2%), and pneumonia (3.2%).
• 29% of patients experienced a dose reduction. Side effects that led to dose reduction in more than 3% of patients included keratopathy (23%) and decreased platelets (5%).
• 8% of patients discontinued treatment permanently. This was most commonly due to keratopathy (2.1%).

Support the Care and Dosing
Your healthcare provider will determine how many treatments you get based on your eye exams*

Enrollment in the BLENREP REMS
Baseline eye exam prior to first dose
First dose of BLENREP
Infusion every 3 weeks, with eye exam prior to each infusion

*Diagram represents requirements related to the BLENREP REMS and is not inclusive. Your healthcare provider may change your treatment based on other factors.

IMPORTANT SAFETY INFORMATION (CONT’D)
- are pregnant or plan to become pregnant. BLENREP can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider may do a pregnancy test before you start treatment with BLENREP. You should use effective birth control during treatment with BLENREP and for 4 months after the last dose. Talk to your healthcare provider about birth control methods you can use during this time. Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with BLENREP. Males with female partners who are able to become pregnant should use effective birth control during treatment with BLENREP and for 6 months after the last dose.
- are breastfeeding or plan to breastfeed. It is not known if BLENREP passes into your breast milk. Do not breastfeed during treatment with BLENREP and for 3 months after the last dose.

Please see IMPORTANT SAFETY INFORMATION continued throughout and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.

IMPORTANT SAFETY INFORMATION (CONT’D)
- BLENREP may affect fertility in males and females. Talk to your healthcare provider if this is a concern for you.

Eye exams show that you can continue to receive BLENREP.

Based on eye exam results, your healthcare provider may decide to continue treatment at a decreased dose, temporarily stop and later resume at the same or a reduced dose, or completely stop treatment.

Further information is available at BLENREPREMS.com and 1-855-209-9188
Before treatment

Tell your healthcare provider about all your medical conditions, including if you:

• Have a history of vision or eye problems
• Have bleeding problems or a history of bleeding problems
• Are pregnant or plan to become pregnant. BLENREP can harm your unborn baby
• Are breastfeeding or plan to breastfeed. It is not known if BLENREP passes into your breast milk

Tell your healthcare provider about all the medications you take, including:

• Prescription and over-the-counter medicines
• Vitamins and herbal supplements

Review your REMS Patient Guide prior to your first infusion

You will need to receive important exams:

• **Eye exam:** Your healthcare provider will send you to an eye specialist to check your eyes before you start treatment with BLENREP.

• **Pregnancy test:** Your healthcare provider may do a pregnancy test before you start treatment, as BLENREP may harm your unborn baby.

• **Blood cell counts**

During treatment

• Monitor and tell your healthcare provider if you have any symptoms and side effects

• Tell your healthcare provider if you have any vision changes or eye problems during treatment with BLENREP. You will receive an eye exam prior to each dose of BLENREP and for worsening symptoms of eye problems as required by the BLENREP REMS. Eye exams are important, as some changes can happen without symptoms and may only be seen on an eye exam.

• Use preservative-free lubricant eye drops 4 times each day throughout your treatment with BLENREP as instructed by your healthcare provider. Guidance on using eye drops is provided at eyedropinstructions.com.

• Don’t wear contact lenses, unless your healthcare provider advises you to. If you normally wear contact lenses, you can plan to use a pair of eyeglasses while taking BLENREP.

• Use caution when driving or operating machinery.

• Tell your healthcare provider if you have bleeding or bruising during treatment with BLENREP.

• Tell your healthcare provider or nurse right away if you get any of the following signs or symptoms of an infusion reaction while receiving BLENREP:
  - chills or shaking
  - shortness of breath, cough, or wheezing
  - redness of your face (flushing)
  - swelling of your lips, tongue, or throat
  - itching or rash
  - dizziness
  - feel like passing out
  - tiredness
  - fever
  - feel like your heart is racing (palpitations)

• It is important for patients who are able to become pregnant, and males with female partners who are able to become pregnant, to use effective contraception. Talk to your healthcare provider about birth control methods you can use during this time.

• Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with BLENREP.

• Do not breastfeed during treatment with BLENREP and for at least 3 months after the last dose.

After treatment

Talk to your healthcare provider before stopping your contraception

• Males with female partners who are able to become pregnant should use effective contraception for at least 6 months after the last dose of BLENREP.

• Patients who are able to become pregnant should continue to use effective contraception for at least 4 months after the last dose of BLENREP.

If you experience any side effects while taking BLENREP, it is important to contact your healthcare provider.
**BLENREP patient support is available**

**Support staff** are available to help with your questions and concerns, including:

- What to expect during administration of BLENREP
- What to do if you experience side effects
- Education about multiple myeloma

Sign up at BLENREP.com to receive information and updates from the patient support program.

The **eye care professional locator tool** will provide assistance finding an eye care professional near you for the eye exams required throughout your treatment.

Visit BLENREP.com/find-an-eye-care-professional.

**Together with GSK Oncology (TwGO)** offers a variety of patient access and reimbursement resources in one easy-to-access location.

- Co-pay assistance for eligible patients with commercial or private prescription insurance.
- Information about insurance coverage and costs for your GSK medicine.
- Patient Assistance Program, offering GSK medicines for free for eligible patients, including patients with no prescription drug coverage for their GSK medicine or Medicare patients who qualify for the program.
- Information about other organizations or independent foundations that may be able to help with GSK medicine costs.

To assist patients with the management of eye problems, TwGO also offers Ophthalmic Support Services to patients who enroll in the program, including:

- Ophthalmic (ophthalmology and optometry) insurance verification
- Finding an eye care professional
- Ophthalmic appointment scheduling and reminders

We’re here to help answer many of your questions. Visit BLENREP.com or call 1-844-4GSK-ONC (1-844-447-5662) from 8 am to 8 pm ET

**REMS resources available to you.** In addition to counseling from your healthcare provider, a REMS Patient Guide with education on the risk and management of eye problems is available. Visit BLENREPREMS.com or call 1-855-209-9188 from 8 am to 8 pm ET for more information.

If you have additional questions about eye care management, ask your healthcare provider.

---

**If you are a caregiver, we recognize the critical role you play in a patient’s life. There are ways you can help**

- Assist with transportation to the healthcare provider and eye care professional appointments.
- Take notes when the healthcare provider explains the BLENREP REMS so you both will know the requirements of the program.
- Help monitor any side effects or vision changes.
- Attend healthcare provider office visits and help get questions answered about the treatment journey with BLENREP.
- Be mindful of your own health and well-being.
- Consider finding a support group in your local area to connect with people who share the same journey.
- Help patients connect with others through patient advocacy groups, like Myeloma Crowd, Leukemia & Lymphoma Society, Multiple Myeloma Research Foundation, or International Myeloma Foundation.

“Being proactive sets the stage for how you’re going to deal with myeloma and it helps find what’s best for you.”

– Kathy, BLENREP patient since November 2020

**IMPORTANT SAFETY INFORMATION (CONT’D)**

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. These are not all the possible side effects of BLENREP.

Please see IMPORTANT SAFETY INFORMATION continued throughout and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.
Frequently asked questions

Who can take BLENREP?
BLENREP is a prescription medicine used to treat adults with multiple myeloma who have received at least 4 prior medicines to treat multiple myeloma, and their cancer has come back or did not respond to prior treatment.

BLENREP is approved based on patient response rate. Studies are ongoing to confirm the clinical benefit of BLENREP for this use.

If BLENREP is right for me, how do I become eligible to receive it?
You must be enrolled in the BLENREP REMS and follow the REMS requirements for eye exams in order to receive BLENREP. Because of the risk of eye problems, your eyes, including your vision, are monitored as part of the BLENREP REMS.

How does BLENREP work differently from other multiple myeloma treatments?
BLENREP works differently from other multiple myeloma medications. It is the first and only ADC that targets BCMA, and also uses your body’s own immune system to recognize and attack the cancerous myeloma cells.

How often should I receive BLENREP?
BLENREP is an infusion that is administered for at least 30 minutes, usually every 3 weeks. Your healthcare provider will decide how many treatments you need. Your healthcare provider may decrease your dose, temporarily stop or completely stop treatment with BLENREP if you have serious side effects. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

Do I need to take steroids or other multiple myeloma treatments in combination with BLENREP?
BLENREP is used alone in the treatment of multiple myeloma. However, if you have an infusion-related reaction during treatment, your healthcare provider will pause treatment and resume your dose at a slower rate (infused over a longer period of time) after symptoms resolve. Your healthcare provider may consider premedication, including a steroid, for any future infusions. You should use preservative-free lubricant eye drops at least 4 times per day during treatment with BLENREP.

What most common side effects should I be aware of during treatment with BLENREP?
The most common side effects of BLENREP include vision or eye changes such as findings on eye exam (keratopathy), decreased vision or blurred vision, nausea, low blood cell counts, fever, infusion-related reactions, tiredness, and changes in kidney or liver function blood tests. These are not all the possible side effects of BLENREP.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Did BLENREP cause permanent, complete vision loss in the study?
No permanent, complete vision loss was reported in the pivotal study. Because of the risk of eye problems, your eye health including vision is monitored as part of the BLENREP REMS.

If my dose is delayed or interrupted, can I resume treatment with BLENREP?
Your healthcare provider may decrease your dose, temporarily stop or completely stop treatment with BLENREP if you have serious side effects. Your healthcare provider will determine the most appropriate option for you.

How do I find an eye care professional for my eye exams?
Your oncologist may already have an eye doctor to partner with during treatment. However, if you already have an eye doctor that you visit for your eye health, then you can ask your oncologist to reach out to coordinate with them. You can also use the eye care professional locator tool at BLENREP.com/find-an-eye-care-professional.

What will be the timing between my eye exam to infusion?
Your eye exams need to be completed within 2 weeks prior to each infusion.

How will my eye exams results get reviewed by my doctor?
Your eye doctor and oncologist will review your eye exam results before each infusion. You can always ask about your results while on treatment with BLENREP.

Is there patient support available with BLENREP?
Support staff are available to help with your questions and concerns. Sign up at BLENREP.com to receive information and updates from the patient support program.

Together with GSK Oncology offers a variety of patient access and reimbursement resources.

The eye care professional locator tool will provide assistance finding an eye care professional near you for the eye exams required throughout your treatment. Visit BLENREP.com/find-an-eye-care-professional.

REMS resources are available to you. In addition to counseling from your healthcare provider, a REMS Patient Guide with education on the risk and management of eye problems is available. Visit BLENREPREMS.com or call 1-855-209-9188 from 8 am to 8 pm ET for more information.

If you have additional questions about eye care management, ask your healthcare provider.

Please see IMPORTANT SAFETY INFORMATION continued throughout and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.
What does it mean to have relapsed or refractory multiple myeloma?

Multiple myeloma is a blood cancer that starts in plasma cells, which are white blood cells that normally fight infections.

- Multiple myeloma develops after healthy plasma cells, located in the bone marrow, mutate into cancerous myeloma cells.
- Immature plasma cells are produced in the bone marrow and then form into healthy mature plasma cells. With multiple myeloma, immature plasma cells develop into cancerous myeloma cells instead, which crowd out healthy cells in the bone marrow.
- When these cells become cancerous, they stop producing normal antibodies and produce antibodies that do not help the body.
- The cancerous myeloma cells grow uncontrollably, crowding out new healthy blood cells made in the bone marrow, including red blood cells, white blood cells, and platelets.
- The cancerous myeloma cells can overtake normal blood cells in the bone marrow, destroy bone tissue, and spread all over the body.

**Relapse:** The return of the disease or signs and symptoms of the disease after a period of improvement.

**Refractory disease:** When a disease does not respond to a treatment.

IMPORTANT SAFETY INFORMATION

**What is the most important information I should know about BLENREP?**

Before you receive BLENREP, you must read and agree to all of the instructions in the BLENREP REMS. Before prescribing BLENREP, your healthcare provider will explain the BLENREP REMS to you and have you sign the Patient Enrollment Form.

**BLENREP can cause serious side effects, including:**

**Eye problems.** Eye problems are common with BLENREP. BLENREP can cause changes to the surface of your eye that can lead to dry eyes, blurred vision, worsening vision, severe vision loss, and corneal ulcer. Tell your healthcare provider if you have any vision changes or eye problems during treatment with BLENREP.

Please see IMPORTANT SAFETY INFORMATION continued throughout and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.
IMPORTANT SAFETY INFORMATION (CONT’D)

• Your healthcare provider will send you to an eye specialist to check your eyes before you start treatment with BLENREP, prior to each dose of BLENREP, and for worsening symptoms of eye problems.

• Even if your vision seems fine, it is important that you get your eyes checked during treatment with BLENREP because some changes can happen without symptoms and may only be seen on an eye exam.

• You should use preservative-free lubricant eye drops at least 4 times per day during treatment with BLENREP as instructed by your healthcare provider.

• You should use caution when driving or operating machinery as BLENREP may affect your vision.

• Avoid wearing contact lenses during treatment with BLENREP unless directed by your eye specialist.

Meet Kathy

• Kathy is a 59-year-old active wife, mother, and former substitute teacher.

• She has been on more than 9 treatment regimens for multiple myeloma since she was diagnosed in 2001. One was a single therapy with a proteasome inhibitor, another combined an immunomodulatory agent and steroid, and another regimen included an anti-CD38 monoclonal antibody. She responded to some of them, but in early 2020 her body stopped responding and her cancer became aggressive.

• Kathy talked about BLENREP with her healthcare provider, got enrolled in the BLENREP REMS and got her first treatment in early November of 2020. Kathy responded to BLENREP treatment despite having stopped responding to more than 9 other prior treatment regimens. She has experienced some joint pain, blurred vision, and dry eye, which she manages with eye drops during the day and ointment at night.

• Her nurse practitioner, oncologist, and eye doctor have been supporting her throughout her treatment experience.

“BLENREP has worked for me. It is helping me stay positive and stay ahead of this disease.”

– Kathy, BLENREP patient since November 2020

“My journey is unique to me, but as of now, I’m keeping a positive outlook for myself, my family, and my friends.”

– Kathy, BLENREP patient since November 2020

Do you have experience with BLENREP? Your perspective can empower and encourage others. If you’re interested in sharing your story, we’d love to hear from you. Call 1-877-268-0443 to learn more.

Please see IMPORTANT SAFETY INFORMATION continued throughout and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.
Meet other patients on BLENREP to learn about their experiences on treatment.

To learn more, visit BLENREP.com or call 1-844-4GSK-ONC (1-844-447-5662)

Please see IMPORTANT SAFETY INFORMATION starting on front cover and accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.